Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02792725
Expanded Access Status : Approved for marketing
First Posted : June 7, 2016
Last Update Posted : October 31, 2017
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Tracking Information
First Submitted Date June 3, 2016
First Posted Date June 7, 2016
Last Update Posted Date October 31, 2017
 
Descriptive Information
Brief Title Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Brief Summary The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Detailed Description Not Provided
Study Type Expanded Access
Intervention Drug: Abemaciclib
Administered orally
Other Name: LY2835219
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status Approved for marketing
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT02792725
Responsible Party Eli Lilly and Company
Study Sponsor Eli Lilly and Company
Collaborators Not Provided
Investigators
Study Director: Contact Lilly at 1-800-LillyRx (1-800-545-5979) Eli Lilly and Company
PRS Account Eli Lilly and Company
Verification Date October 2017